The CSO of Arbutus Biopharma Corporation (ABUS) is Selling Shares


Today, the CSO of Arbutus Biopharma Corporation (NASDAQ: ABUS), Michael Sofia, sold shares of ABUS for $40.42K.

Following Michael Sofia’s last ABUS Sell transaction on August 17, 2017, the stock climbed by 6.0%.

See today’s analyst top recommended stocks >>

Based on Arbutus Biopharma Corporation’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $1.24 million and quarterly net profit of $3.09 million. In comparison, last year the company earned revenue of $1.04 million and had a GAAP net loss of $18.26 million. Currently, Arbutus Biopharma Corporation has an average volume of 390K.

Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $10.17, reflecting a -9.5% downside.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arbutus Biopharma Corp. is a biopharmaceutical company, engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts